We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

VEGF-Expressing TAMs Linked to Improved Colon Ca Survival

Aug 1, 2003
Volume: 
12
Issue: 
8
  • Colorectal Cancer

ROCHESTER, New York—Control of colon cancer may be
mediated in part by the patient’s immune system, suggesting that treatments
that enhance this innate capability could aid in reducing mortality. This is
the principal conclusion taken from work carried out by Alok Khorana, MD, and
his colleagues at the James P. Wilmot Cancer Center, University of Rochester
Medical Center, and presented at the American Association for Cancer Research
94th Annual Meeting (abstract 512).

The study involved immunocyto-chemical staining of
paraffin-embedded stage II and III primary colon cancer tumors from 131
patients, seen at the University of Rochester from 1990 to 1995, and focused
on vascular endothelial growth factor (VEGF), a protein that is overexpressed
in a variety of cancers, often with an associated increase in severity of
disease.

In addition to examining VEGF expression in the tumor
itself, the investigators also measured its appearance in the surrounding
tissue stroma, paying particular attention to its association with
tumor-associated macrophages (TAMs). Sections were also stained for the
antigens C68, a marker for macrophages, and CD3, a marker for T lymphocytes.

Immunostains were separately graded as the percentage of
cells stained with moderate or greater intensity according to the following
scale: negative, less than 2%; grade 1, 2% to 20%; grade 2, 20% to 50%; grade
3, greater than 50%. The degree of staining was further correlated with length
of survival after resection of the primary tumor. Data were analyzed using a
multivariate Cox proportional hazards model.

Study Results

Despite its frequent association with more severe disease,
VEGF expression in the tumor itself was not significantly associated with
survival. In contrast, there was a clear relationship between survival and
VEGF expression in TAMs; 42% of patients showed this expression pattern, and
median survival in this group was more than doubled, to 9.7 years vs 4.3 years
in the VEGF-negative TAMs group (P = .0065).

Thus, rather than being associated with reduced survival,
increased VEGF expression in one subset of tumor-associated cells actually
predicted a more positive outcome. Confirmation that the stromal cells that
expressed VEGF were indeed macrophages came from co-staining for the
macrophage marker CD68; the great majority of VEGF-expressing cells were
macrophages, with the remainder being fibroblasts. The VEGF-expressing TAMs
comprised only a subset of the macrophages in the stroma, however, and in
multivariate analysis, there was no association between survival and CD68
expression alone. It was accordingly inferred that the improved survival was a
function of the presence of the VEGF-expressing TAMs subgroup, rather than of
all macrophages.

One clue as to the possible mechanism mediating the link
between increased survival and the presence of VEGF-expressing TAMs came from
the examination of T-lymphocyte infiltration, as determined from the pattern
of CD3 immunostaining. Only those tumors with VEGF-expressing TAMs showed
significant infiltration of T cells (n = 10; P = .0003). Thus, it is
possible that VEGF expression by TAMs is associated with mobilization of the T
cells that are involved in a host immune response against the tumor.

"At present, we have only a correlation between VEGF-expressing
TAMs and two other parameters, survival and T-cell infiltration, so that
suggestions as to underlying mechanisms must still be regarded as
speculative," he said. One possibility is that the macrophages are acting
as antigen-presenting cells, and that T cells have been mobilized to the tumor
in response to specific tumor antigens displayed by the macrophages.
"While the correlation with VEGF expression seems clear, it remains a
puzzle as to what role, if any, their VEGF expression plays in this
process," he said. "It may be, in fact, that it is only acting as a
surrogate marker of the activation of immune-related processes in given
cells."

In this connection, he said, it has recently been reported
that the transcription factor HIf-1α is essential for the activation of
cellular inflammatory pathways (Cramer et al: Cell 112:645-657, 2003).
"Since HIf-1a also upregulates VEGF expression, our correlations with
increased patient survival may reflect the impact of overall activation of
this subset of macrophages, not their VEGF expression as such," he said.

This could also explain why VEGF production by the tumor
itself is not protective. However, he noted that VEGF is present in several
isoforms, and the antibody used in the current study does not discriminate
among them. It remains to be seen whether the macrophage-associated VEGF and
the tumor forms are identical or different, he said.

"Obviously," Dr. Khorana said, "there is still a substantial
amount of work to be done to understand these phenomena. Nonetheless, we
believe that the most likely explanation for the improved survival associated
with VEGF-expressing TAMs is an involvement of the host immune response in
controlling the tumor. The implications are that further modulation of the
immune response through therapeutic intervention may improve the prognosis for
colon cancer." Some of this work has since been published (Khorana AA et
al: Cancer 97:960-968, 2003).

Related Articles

  • Inhibit CXCR4 to Treat CRC and Pancreatic Cancer
  • ACS Nutrition, Activity Guidelines Boost Survival in Stage III CRC
  • Modified XELIRI Noninferior to FOLFIRI for Metastatic CRC
  • A3AR Agonists May Help Prevent Chemotherapy-Induced Neuropathic Pain
  • Less Risk of Distal Colon Cancer With Lower Red Meat Intake?

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.